Browsed by
Month: January 2011

New Solid Phase Assay Coming Soon

New Solid Phase Assay Coming Soon

TopoGEN scientists have developed a novel solid phase screening assay suitable for High Throughput Screening. This method has the ability to unambiguously identify topoisomerase targeting drugs. In addition, this HTS method will predict if a test drug is an INTERFACIAL POISON or a CATALYTIC INHIBITOR. Stay tuned for more details! The paper has been submitted for publication and will be released on this blog. In the meantime feel free to contact us with any questions about this exciting new development.

Findings of PARP Inhibitors Study at NIH

Findings of PARP Inhibitors Study at NIH

Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells. Zhang YW, Regairaz M, Seiler JA, Agama KK, Doroshow JH, Pommier Y. Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, MD 20892, USA. Abstract Poly(ADP-Ribose) (PAR) polymerase (PARP) inhibitors represent a promising class of novel anticancer agents. The present study explores the molecular rationale for combining veliparib (ABT-888) with camptothecin (CPT) and its…

Read More Read More